

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**APPROVAL PACKAGE FOR:**

**APPLICATION NUMBER**

**NDA 21-492/S-002**

**Approved Labeling**

**ELOXATIN™**  
**(oxaliplatin for injection)**


**WARNING**

ELOXATIN (oxaliplatin for injection) should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available.

Anaphylactic-like reactions to ELOXATIN have been reported, and may occur within minutes of ELOXATIN administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms. (See WARNINGS and ADVERSE REACTIONS).

**DESCRIPTION**

ELOXATIN™ (oxaliplatin for injection) is an antineoplastic agent with the molecular formula  $C_8H_{14}N_2O_4Pt$  and the chemical name of *cis*-[(1*R*,2*R*)-1,2-cyclohexanediamine-*N,N'*] [oxalato(2-)-*O,O'*] platinum. Oxaliplatin is an organoplatinum complex in which the platinum atom is complexed with 1,2- diaminocyclohexane (DACH) and with an oxalate ligand as a leaving group.



The molecular weight is 397.3. Oxaliplatin is slightly soluble in water at 6 mg/mL, very slightly soluble in methanol, and practically insoluble in ethanol and acetone.

ELOXATIN is supplied in vials containing 50 mg or 100 mg of oxaliplatin as a sterile, preservative-free lyophilized powder for reconstitution. Lactose monohydrate is present as an inactive ingredient at 450 mg and 900 mg in the 50 mg and 100 mg dosage strengths, respectively.

## 23 CLINICAL PHARMACOLOGY

24

### 25 Mechanism of Action

26 Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives  
27 via displacement of the labile oxalate ligand. Several transient reactive species are formed,  
28 including monoaquo and diaquo DACH platinum, which covalently bind with  
29 macromolecules. Both inter- and intra-strand Pt-DNA cross-links are formed. Crosslinks are  
30 formed between the N7 positions of two adjacent guanines (GG), adjacent adenine-guanines  
31 (AG), and guanines separated by an intervening nucleotide (GNG). These crosslinks inhibit  
32 DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.

33

### 34 Pharmacology

35 *In vivo* studies have shown antitumor activity of oxaliplatin against colon carcinoma. In  
36 combination with 5-fluorouracil (5-FU), oxaliplatin exhibits *in vitro* and *in vivo*  
37 antiproliferative activity greater than either compound alone in several tumor models [HT29  
38 (colon), GR (mammary), and L1210 (leukemia)].

39

### 40 Human Pharmacokinetics

41 The reactive oxaliplatin derivatives are present as a fraction of the unbound platinum in  
42 plasma ultrafiltrate. The decline of ultrafilterable platinum levels following oxaliplatin  
43 administration is triphasic, characterized by two relatively short distribution phases ( $t_{1/2\alpha}$ ; 0.43  
44 hours and  $t_{1/2\beta}$ ; 16.8 hours) and a long terminal elimination phase ( $t_{1/2\gamma}$ ; 391 hours).  
45 Pharmacokinetic parameters obtained after a single 2-hour IV infusion of ELOXATIN at a dose  
46 of 85 mg/m<sup>2</sup> expressed as ultrafilterable platinum were C<sub>max</sub> of 0.814 µg/mL and volume of  
47 distribution of 440 L.

48

49 Interpatient and inpatient variability in ultrafilterable platinum exposure (AUC<sub>0-48</sub>)  
50 assessed over 3 cycles was moderate to low (23% and 6%, respectively). A pharmacodynamic  
51 relationship between platinum ultrafiltrate levels and clinical safety and effectiveness has not  
52 been established.

53

### 54 Distribution

55 At the end of a 2-hour infusion of ELOXATIN, approximately 15% of the administered  
56 platinum is present in the systemic circulation. The remaining 85% is rapidly distributed into  
57 tissues or eliminated in the urine. In patients, plasma protein binding of platinum is  
58 irreversible and is greater than 90%. The main binding proteins are albumin and gamma-  
59 globulins. Platinum also binds irreversibly and accumulates (approximately 2-fold) in  
60 erythrocytes, where it appears to have no relevant activity. No platinum accumulation was  
61 observed in plasma ultrafiltrate following 85 mg/m<sup>2</sup> every two weeks.

62

## 63 Metabolism

64 Oxaliplatin undergoes rapid and extensive nonenzymatic biotransformation. There is no  
65 evidence of cytochrome P450-mediated metabolism *in vitro*.

66  
67 Up to 17 platinum-containing derivatives have been observed in plasma ultrafiltrate samples  
68 from patients, including several cytotoxic species (monochloro DACH platinum, dichloro  
69 DACH platinum, and monoquo and diaquo DACH platinum) and a number of noncytotoxic,  
70 conjugated species.

## 71 72 Elimination

73 The major route of platinum elimination is renal excretion. At five days after a single 2-hour  
74 infusion of ELOXATIN, urinary elimination accounted for about 54% of the platinum  
75 eliminated, with fecal excretion accounting for only about 2%. Platinum was cleared from  
76 plasma at a rate (10 – 17 L/h) that was similar to or exceeded the average human glomerular  
77 filtration rate (GFR; 7.5 L/h). There was no significant effect of gender on the clearance of  
78 ultrafilterable platinum. The renal clearance of ultrafilterable platinum is significantly  
79 correlated with GFR. (See ADVERSE REACTIONS)

## 80 81 Pharmacokinetics in Special Populations

### 82 Renal Impairment

83  
84 The AUC<sub>0-48hr</sub> of platinum in the plasma ultrafiltrate increases as renal function decreases.  
85 The AUC<sub>0-48hr</sub> of platinum in patients with mild (creatinine clearance, CL<sub>cr</sub> 50 to 80 mL/min),  
86 moderate (CL<sub>cr</sub> 30 to <50 mL/min) and severe renal (CL<sub>cr</sub> <30 mL/min) impairment is  
87 increased by about 60, 140 and 190%, respectively, compared to patients with normal renal  
88 function (CL<sub>cr</sub> >80 mL/min)]. (See PRECAUTIONS and ADVERSE REACTIONS)

### 89 90 Drug - Drug Interactions

91 No pharmacokinetic interaction between 85 mg/m<sup>2</sup> of ELOXATIN and 5-FU has been observed  
92 in patients treated every 2 weeks, but increases of 5-FU plasma concentrations by  
93 approximately 20% have been observed with doses of 130 mg/m<sup>2</sup> of ELOXATIN administered  
94 every 3 weeks. *In vitro*, platinum was not displaced from plasma proteins by the following  
95 medications: erythromycin, salicylate, sodium valproate, granisetron, and paclitaxel. *In vitro*,  
96 oxaliplatin is not metabolized by, nor does it inhibit, human cytochrome P450 isoenzymes.  
97 No P450-mediated drug-drug interactions are therefore anticipated in patients.

98  
99 Since platinum containing species are eliminated primarily through the kidney, clearance of  
100 these products may be decreased by co-administration of potentially nephrotoxic compounds,  
101 although this has not been specifically studied.

102

## CLINICAL STUDIES

### Combination Therapy with ELOXATIN and 5-FU/LV in Patients Previously Untreated for Advanced Colorectal Cancer

A North American, multicenter, open-label, randomized controlled study was sponsored by the National Cancer Institute (NCI) as an intergroup study led by the North Central Cancer Treatment Group (NCCTG). The study had 7 arms at different times during its conduct, four of which were closed due to either changes in the standard of care, toxicity, or simplification. During the study, the control arm was changed to irinotecan plus 5-FU/LV. The results reported below compared the efficacy and safety of two experimental regimens, ELOXATIN in combination with infusional 5-FU/LV and a combination of ELOXATIN plus irinotecan, to an approved control regimen of irinotecan plus 5-FU/LV in 795 concurrently randomized patients previously untreated for locally advanced or metastatic colorectal cancer. After completion of enrollment, the dose of irinotecan plus 5-FU/LV was decreased due to toxicity. Patients had to be at least 18 years of age, have known locally advanced, locally recurrent, or metastatic colorectal adenocarcinoma not curable by surgery or amenable to radiation therapy with curative intent, histologically proven colorectal adenocarcinoma, measurable or evaluable disease, with an ECOG performance status 0, 1, or 2. Patients had to have granulocyte count  $\geq 1.5 \times 10^9/\text{L}$ , platelets  $\geq 100 \times 10^9/\text{L}$ , hemoglobin  $\geq 9.0 \text{ gm/dL}$ , creatinine  $\leq 1.5 \times \text{ULN}$ , total bilirubin  $\leq 1.5 \text{ mg/dL}$ , AST  $\leq 5 \times \text{ULN}$ , and alkaline phosphatase  $\leq 5 \times \text{ULN}$ . Patients may have received adjuvant therapy for resected Stage II or III disease without recurrence within 12 months. The patients were stratified for ECOG performance status (0, 1 vs. 2), prior adjuvant chemotherapy (yes vs. no), prior immunotherapy (yes vs. no), and age ( $<65$  vs.  $\geq 65$  years). Although no post study treatment was specified in the protocol, 65 to 72% of patients received additional post study chemotherapy after study treatment discontinuation on all arms. Fifty eight percent of patients on the ELOXATIN plus 5-FU/LV arm received an irinotecan-containing regimen and 23% of patients on the irinotecan plus 5-FU/LV arm received oxaliplatin-containing regimens. Oxaliplatin was not commercially available during the trial.

132 The following table presents the dosing regimens of the three arms of the study.

133

134 **Table 1 – Dosing Regimens in Patients Previously Untreated for Advanced Colorectal**  
135 **Cancer Clinical Trial**

| Treatment Arm                      | Dose                                                                                                                                                                                                                                                                                                                                            | Regimen |
|------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| ELOXATIN + 5-FU/LV FOLFOX4 (N=267) | Day 1: ELOXATIN: 85 mg/m <sup>2</sup> (2-hour infusion) + LV 200 mg/m <sup>2</sup> (2-hour infusion), followed by 5-FU: 400 mg/m <sup>2</sup> (bolus), 600 mg/m <sup>2</sup> (22-hour infusion)<br>Day 2: LV 200 mg/m <sup>2</sup> (2-hour infusion), followed by 5-FU: 400 mg/m <sup>2</sup> (bolus), 600 mg/m <sup>2</sup> (22-hour infusion) | q2w     |
| irinotecan + 5-FU/LV IFL (N=264)   | Day 1: irinotecan 125 mg/m <sup>2</sup> as a 90-min infusion +LV 20 mg/m <sup>2</sup> as a 15-min infusion or IV push, followed by 5-FU 500 mg/m <sup>2</sup> IV bolus weekly x 4                                                                                                                                                               | q6w     |
| ELOXATIN + Irinotecan IROX (N=264) | Day 1: ELOXATIN: 85 mg/m <sup>2</sup> IV (2-hour infusion) + irinotecan 200 mg/m <sup>2</sup> IV over 30 minutes.                                                                                                                                                                                                                               | q3w     |

136

137 The following table presents the demographics and dosing of the patient population entered  
 138 into this study.

139 **Table 2 – Patient Demographics and Dosing in Patients Previously Untreated for**  
 140 **Advanced Colorectal Cancer Clinical Trial**

141

|                               | ELOXATIN +<br>5-FU/LV<br>N=267 | irinotecan +<br>5-FU/LV<br>N=264 | ELOXATIN +<br>irinotecan<br>N=264 |
|-------------------------------|--------------------------------|----------------------------------|-----------------------------------|
| Sex: Male (%)                 | 58.8                           | 65.2                             | 61.0                              |
| Female (%)                    | 41.2                           | 34.8                             | 39.0                              |
| Median age (years)            | 61.0                           | 61.0                             | 61.0                              |
| <65 years of age (%)          | 61                             | 62                               | 63                                |
| ≥65 years of age (%)          | 39                             | 38                               | 37                                |
| ECOG (%)                      |                                |                                  |                                   |
| 0,1                           | 94.4                           | 95.5                             | 94.7                              |
| 2                             | 5.6                            | 4.5                              | 5.3                               |
| Involved organs (%)           |                                |                                  |                                   |
| Colon only                    | 0.7                            | 0.8                              | 0.4                               |
| Liver only                    | 39.3                           | 44.3                             | 39.0                              |
| Liver + other                 | 41.2                           | 38.6                             | 40.9                              |
| Lung only                     | 6.4                            | 3.8                              | 5.3                               |
| Other (including lymph nodes) | 11.6                           | 11.0                             | 12.9                              |
| Not reported                  | 0.7                            | 1.5                              | 1.5                               |
| Prior radiation (%)           | 3.0                            | 1.5                              | 3.0                               |
| Prior surgery (%)             | 74.5                           | 79.2                             | 81.8                              |
| Prior adjuvant (%)            | 15.7                           | 14.8                             | 15.2                              |

142

143 The length of a treatment cycle was 2 weeks for the ELOXATIN and 5-FU/LV regimen; 6  
 144 weeks for the irinotecan plus 5-FU/LV regimen; and 3 weeks for the ELOXATIN plus  
 145 irinotecan regimen. The median number of cycles administered per patient was 10 (23.9  
 146 weeks) for the ELOXATIN and 5-FU/LV regimen, 4 (23.6 weeks) for the irinotecan plus 5-  
 147 FU/LV regimen, and 7 (21.0 weeks) for the ELOXATIN plus irinotecan regimen.

148

149 Patients treated with the ELOXATIN and 5-FU/LV combination had a significantly longer time  
 150 to tumor progression based on investigator assessment, longer overall survival, and a  
 151 significantly higher confirmed response rate based on investigator assessment compared to  
 152 patients given irinotecan plus 5-FU/LV. The following table summarizes the efficacy results.

153 **Table 3 – Summary of Efficacy**

|                                                  | <b>ELOXATIN +<br/>5-FU/LV<br/>N=267</b> | <b>irinotecan +<br/>5-FU/LV<br/>N=264</b> | <b>ELOXATIN + irinotecan<br/>N=264</b> |
|--------------------------------------------------|-----------------------------------------|-------------------------------------------|----------------------------------------|
| <b>Survival (ITT)</b>                            |                                         |                                           |                                        |
| Number of deaths N (%)                           | 155 (58.1)                              | 192 (72.7)                                | 175 (66.3)                             |
| Median survival (months)                         | 19.4                                    | 14.6                                      | 17.6                                   |
| Hazard Ratio and (95% confidence interval)       | 0.65 (0.53-0.80)*                       |                                           |                                        |
| P-value                                          | <0.0001*                                | -                                         | -                                      |
| <b>TTP (ITT, investigator assessment)</b>        |                                         |                                           |                                        |
| Percentage of progressors                        | 82.8                                    | 81.8                                      | 89.4                                   |
| Median TTP (months)                              | 8.7                                     | 6.9                                       | 6.5                                    |
| Hazard Ratio and (95% confidence interval)       | 0.74 (0.61-0.89)*                       |                                           |                                        |
| P-value                                          | 0.0014*                                 | -                                         | -                                      |
| <b>Response Rate (investigator assessment)**</b> |                                         |                                           |                                        |
| Patients with measurable disease                 | 210                                     | 212                                       | 215                                    |
| Complete response N (%)                          | 13 (6.2)                                | 5 (2.4)                                   | 7 (3.3)                                |
| Partial response N (%)                           | 82 (39.0)                               | 64 (30.2)                                 | 67 (31.2)                              |
| Complete and partial response N (%)              | 95 (45.2)                               | 69 (32.5)                                 | 74 (34.4)                              |
| 95% confidence interval                          | (38.5 – 52.0)                           | (26.2 – 38.9)                             | (28.1 – 40.8)                          |
| P-value                                          | 0.0080*                                 | -                                         | -                                      |

154 \*Compared to irinotecan plus 5-FU/LV (IFL) arm

155 \*\*Based on all patients with measurable disease at baseline

156


157 The numbers in the response rate and TTP analysis are based on unblinded investigator  
 158 assessment.



159

160

161 Figure 1 illustrates the Kaplan-Meier survival curves for the comparison of ELOXATIN and 5-  
162 FU/LV combination and ELOXATIN plus irinotecan to irinotecan plus 5-FU/LV.



\*Log rank test comparing Eloxatin plus 5-FU/LV to irinotecan plus 5-FU/LV.

163

164 A descriptive subgroup analysis demonstrated that the improvement in survival for  
165 ELOXATIN plus 5-FU/LV compared to irinotecan plus 5-FU/LV appeared to be maintained  
166 across age groups, prior adjuvant therapy, and number of organs involved. An estimated  
167 survival advantage in ELOXATIN plus 5-FU/LV versus irinotecan plus 5-FU/LV was seen in  
168 both genders; however it was greater among women than men. Insufficient subgroup sizes  
169 prevented analysis by race.

170

171 **Combination Therapy with ELOXATIN and 5-FU/LV in Previously Treated**  
172 **Patients with Advanced Colorectal Cancer**

173 A multicenter, open-label, randomized, three arm controlled study was conducted in the US  
174 and Canada comparing the efficacy and safety of ELOXATIN in combination with an infusional  
175 schedule of 5-FU/LV to the same dose and schedule of 5-FU/LV alone and to single agent  
176 oxaliplatin in patients with advanced colorectal cancer who had relapsed/progressed during or  
177 within 6 months of first line therapy with bolus 5-FU/LV and irinotecan. The study was  
178 intended to be analyzed for response rate after 450 patients were enrolled. Survival will be  
179 subsequently assessed in all patients enrolled in the completed study. Accrual to this study is  
180 complete, with 821 patients enrolled. Patients in the study had to be at least 18 years of age,  
181 have unresectable, measurable, histologically proven colorectal adenocarcinoma, with a  
182 Karnofsky performance status >50%. Patients had to have SGOT(AST) and SGPT(ALT)  $\leq 2x$   
183 the institution's upper limit of normal (ULN), unless liver metastases were present and  
184 documented at baseline by CT or MRI scan, in which case  $\leq 5x$  ULN was permitted. Patients  
185 had to have alkaline phosphatase  $\leq 2x$  the institution's ULN, unless liver metastases were  
186 present and documented at baseline by CT or MRI scan, in which cases  $\leq 5x$  ULN was  
187 permitted. Prior radiotherapy was permitted if it had been completed at least 3 weeks before  
188 randomization.

189  
190 The dosing regimens of the three arms of the study are presented in the table below.

191  
192 **Table 4 – Dosing Regimens in Refractory and Relapsed**  
193 **Colorectal Cancer Clinical Trial**

| Treatment Arm                    | Dose                                                                                                                                                                                                                                                                                                                                                                | Regime<br>n |
|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| ELOXATIN<br>+ 5-FU/LV<br>(N=152) | Day 1: ELOXATIN: 85 mg/m <sup>2</sup> (2-hour infusion) +<br>LV 200 mg/m <sup>2</sup> (2-hour infusion), followed by 5-<br>FU: 400 mg/m <sup>2</sup> (bolus), 600 mg/m <sup>2</sup> (22-hour<br>infusion)<br><br>Day 2: LV 200 mg/m <sup>2</sup> (2-hour infusion), followed<br>by 5-FU: 400 mg/m <sup>2</sup> (bolus), 600 mg/m <sup>2</sup> (22-hour<br>infusion) | q2w         |
| 5-FU/LV<br>(N=151)               | Day 1: LV 200 mg/m <sup>2</sup> (2-hour infusion), followed by<br>5-FU: 400 mg/m <sup>2</sup> (bolus), 600 mg/m <sup>2</sup> (22-hour<br>infusion)<br><br>Day 2: LV 200 mg/m <sup>2</sup> (2-hour infusion), followed by<br>5-FU: 400 mg/m <sup>2</sup> (bolus), 600 mg/m <sup>2</sup> (22-hour<br>infusion)                                                        | q2w         |
| ELOXATIN<br>(N=156)              | Day 1: ELOXATIN 85 mg/m <sup>2</sup> (2-hour infusion)                                                                                                                                                                                                                                                                                                              | q2w         |

194

Patients entered into the study for evaluation of response must have had at least one unidimensional lesion measuring  $\geq 20$ mm using conventional CT or MRI scans, or  $\geq 10$ mm using a spiral CT scan. Tumor response and progression were assessed every 3 cycles (6 weeks) using the Response Evaluation Criteria in Solid Tumors (RECIST) until radiological documentation of progression or for 13 months following the first dose of study drug(s), whichever came first. Confirmed responses were based on two tumor assessments separated by at least 4 weeks.

The demographics of the patient population entered into this study are shown in the table below.

**Table 5 – Patient Demographics in Refractory and Relapsed Colorectal Cancer Clinical Trial**

|                                | 5-FU/LV<br>(N =<br>151) | ELOXATIN<br>(N = 156) | ELOXATIN +<br>5-FU/LV<br>(N = 152) |
|--------------------------------|-------------------------|-----------------------|------------------------------------|
| Sex: Male (%)                  | 54.3                    | 60.9                  | 57.2                               |
| Female (%)                     | 45.7                    | 39.1                  | 42.8                               |
| Median age (years)             | 60.0                    | 61.0                  | 59.0                               |
| Range                          | 21-80                   | 27-79                 | 22-88                              |
| Race (%)                       |                         |                       |                                    |
| Caucasian                      | 87.4                    | 84.6                  | 88.8                               |
| Black                          | 7.9                     | 7.1                   | 5.9                                |
| Asian                          | 1.3                     | 2.6                   | 2.6                                |
| Other                          | 3.3                     | 5.8                   | 2.6                                |
| KPS (%)                        |                         |                       |                                    |
| 70 – 100                       | 94.7                    | 92.3                  | 95.4                               |
| 50 – 60                        | 2.6                     | 4.5                   | 2.0                                |
| Not reported                   | 2.6                     | 3.2                   | 2.6                                |
| Prior radiotherapy (%)         | 25.2                    | 19.2                  | 25.0                               |
| Prior pelvic radiation (%)     | 18.5                    | 13.5                  | 21.1                               |
| Number of metastatic sites (%) |                         |                       |                                    |
| 1                              | 27.2                    | 31.4                  | 25.7                               |
| $\geq 2$                       | 72.2                    | 67.9                  | 74.3                               |
| Liver involvement (%)          |                         |                       |                                    |
| Liver only                     | 22.5                    | 25.6                  | 18.4                               |
| Liver + other                  | 60.3                    | 59.0                  | 53.3                               |

The median number of cycles administered per patient was 6 for the ELOXATIN and 5-FU/LV combination and 3 each for 5-FU/LV alone and ELOXATIN alone.

Patients treated with the combination of ELOXATIN and 5-FU/LV had an increased response rate compared to patients given 5-FU/LV or oxaliplatin alone. The efficacy results are summarized in the tables below.

216  
217

**Table 6 - Response Rates (ITT Analysis)**

| Best Response | 5-FU/LV<br>(N=151)                        | ELOXATIN<br>(N=156) | ELOXATIN +<br>5-FU/LV<br>(N=152) |
|---------------|-------------------------------------------|---------------------|----------------------------------|
| CR            | 0                                         | 0                   | 0                                |
| PR            | 0                                         | 2 (1%)              | 13 (9%)                          |
| p-value       | 0.0002 for 5-FU/LV vs. ELOXATIN + 5-FU/LV |                     |                                  |
| 95%CI         | 0-2.4%                                    | 0.2-4.6%            | 4.6-14.2%                        |

218

219

**Table 7 - Summary of Radiographic Time to Progression\***

| Arm                                                                | 5-FU/LV<br>(N=151) | ELOXATIN<br>(N=156) | ELOXATIN<br>+ 5-FU/LV<br>(N=152) |
|--------------------------------------------------------------------|--------------------|---------------------|----------------------------------|
| No. of Progressors                                                 | 74                 | 101                 | 50                               |
| No. of patients with no radiological<br>evaluation beyond baseline | 22<br>(15%)        | 16<br>(10%)         | 17<br>(11%)                      |
| Median TTP (months)                                                | 2.7                | 1.6                 | 4.6                              |
| 95% CI                                                             | 1.8-3.0            | 1.4-2.7             | 4.2-6.1                          |

220

221

222

223

224

\*This is not an ITT analysis. Events were limited to radiographic disease progression documented by independent review of radiographs. Clinical progression was not included in this analysis, and 18% of patients were excluded from the analysis based on unavailability of the radiographs for independent review.

225

226

227

228

At the time of the interim analysis 49% of the radiographic progression events had occurred. In this interim analysis an estimated 2-month increase in median time to radiographic progression was observed compared to 5-FU/LV alone.

229

230

231

232

233

Of the 13 patients who had tumor response to the combination of ELOXATIN and 5-FU/LV, 5 were female and 8 were male, and responders included patients <65 years old and ≥65 years old. The small number of non-Caucasian participants made efficacy analyses in these populations uninterpretable.

234

235

## INDICATIONS AND USAGE

236

237

238

ELOXATIN, used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum.

239

240

## CONTRAINDICATIONS

241

242

ELOXATIN should not be administered to patients with a history of known allergy to ELOXATIN or other platinum compounds.

243

244

## **WARNINGS**

245

246

247

248

249

250

251

252

253

254

### **Pregnancy Category D**

255

256

257

258

259

260

261

262

263

ELOXATIN may cause fetal harm when administered to a pregnant woman. Pregnant rats were administered 1 mg/kg/day oxaliplatin (less than one-tenth the recommended human dose based on body surface area) during gestation days 1-5 (pre-implantation), 6-10, or 11-16 (during organogenesis). Oxaliplatin caused developmental mortality (increased early resorptions) when administered on days 6-10 and 11-16 and adversely affected fetal growth (decreased fetal weight, delayed ossification) when administered on days 6-10. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with ELOXATIN.

264

265

## **PRECAUTIONS**

266

267

### **General**

268

269

270

271

ELOXATIN should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available.

## Neuropathy

Neuropathy was graded using a study-specific neurotoxicity scale, which was different than the National Cancer Institute Common Toxicity Criteria, Version 2.0 (NCI CTC) (See below).

In the previously treated study, neuropathy information was collected to establish that ELOXATIN is associated with two types of neuropathy:

- **An acute, reversible, primarily peripheral, sensory neuropathy that is of early onset, occurring within hours or one to two days of dosing, that resolves within 14 days, and that frequently recurs with further dosing.** The symptoms may be precipitated or exacerbated by exposure to cold temperature or cold objects and they usually present as transient paresthesia, dysesthesia and hypoesthesia in the hands, feet, perioral area, or throat. Jaw spasm, abnormal tongue sensation, dysarthria, eye pain, and a feeling of chest pressure have also been observed. The acute, reversible pattern of sensory neuropathy was observed in about 56% of study patients who received ELOXATIN with 5-FU/LV. In any individual cycle acute neurotoxicity was observed in approximately 30% of patients. Ice (mucositis prophylaxis) should be avoided during the infusion of ELOXATIN because cold temperature can exacerbate acute neurological symptoms. (See DOSAGE AND ADMINISTRATION: Dose Modifications).

An acute syndrome of pharyngolaryngeal dysesthesia seen in 1-2% (grade 3/4) of patients previously untreated for advanced colorectal cancer, and the previously treated patients is characterized by subjective sensations of dysphagia or dyspnea, without any laryngospasm or bronchospasm (no stridor or wheezing).

- **A persistent (>14 days), primarily peripheral, sensory neuropathy that is usually characterized by paresthesias, dysesthesias, hypoesthesias, but may also include deficits in proprioception that can interfere with daily activities (e.g. writing, buttoning, swallowing, and difficulty walking from impaired proprioception).** These forms of neuropathy occurred in 48% of the study patients receiving ELOXATIN with 5-FU/LV. Persistent neuropathy can occur without any prior acute neuropathy event. The majority of the patients (80%) who developed grade 3 persistent neuropathy progressed from prior Grade 1 or 2 events. These symptoms may improve in some patients upon discontinuation of ELOXATIN.

Overall, neuropathy was reported in patients previously untreated for advanced colorectal cancer in 82% (all grades) and 19% (grade 3/4), and in the previously treated patients in 74% (all grades) and 7% (grade 3/4) events. Information regarding reversibility of neuropathy was not available from the trial for patients who had not been previously treated for colorectal cancer.

314 Neurotoxicity scale:  
315 The grading scale for paresthesias/dysesthesias was: Grade 1, resolved and did not interfere  
316 with functioning; Grade 2, interfered with function but not daily activities; Grade 3, pain or  
317 functional impairment that interfered with daily activities; Grade 4, persistent impairment that  
318 is disabling or life-threatening.

## 319 320 **Pulmonary Toxicity**

321  
322 ELOXATIN has been associated with pulmonary fibrosis (<1% of study patients), which may be  
323 fatal. The combined incidence of cough, dyspnea and hypoxia was 43% (any grade) and 7%  
324 (grade 3 and 4) in the ELOXATIN plus 5-FU/LV arm compared to 32% (any grade) and 5%  
325 (grade 3 and 4) in the irinotecan plus 5-FU/LV arm of unknown duration for patients with  
326 previously untreated colorectal cancer. In case of unexplained respiratory symptoms such as  
327 non-productive cough, dyspnea, crackles, or radiological pulmonary infiltrates, ELOXATIN  
328 should be discontinued until further pulmonary investigation excludes interstitial lung disease  
329 or pulmonary fibrosis.

## 330 331 332 **Information for Patients**

333 Patients and patients' caregivers should be informed of the expected side effects of ELOXATIN,  
334 particularly its neurologic effects, both the acute, reversible effects, and the persistent  
335 neurosensory toxicity. Patients should be informed that the acute neurosensory toxicity may  
336 be precipitated or exacerbated by exposure to cold or cold objects. Patients should be  
337 instructed to avoid cold drinks, use of ice, and should cover exposed skin prior to exposure to  
338 cold temperature or cold objects.

339 Patients must be adequately informed of the risk of low blood cell counts and instructed to  
340 contact their physician immediately should fever, particularly if associated with persistent  
341 diarrhea, or evidence of infection develop.

342  
343 Patients should be instructed to contact their physician if persistent vomiting, diarrhea, signs  
344 of dehydration, cough or breathing difficulties occur, or signs of allergic reaction appear.

## 345 346 **Laboratory Tests**

347 Standard monitoring of the white blood cell count with differential, hemoglobin, platelet  
348 count, and blood chemistries (including ALT, AST, bilirubin and creatinine) is recommended  
349 before each ELOXATIN cycle (See DOSAGE AND ADMINISTRATION).

## 350 351 **Laboratory Test Interactions**

352 None known.  
353

354 **Carcinogenesis, Mutagenesis, Impairment of Fertility**

355 Long-term animal studies have not been performed to evaluate the carcinogenic potential of  
356 oxaliplatin. Oxaliplatin was not mutagenic to bacteria (Ames test) but was mutagenic to  
357 mammalian cells *in vitro* (L5178Y mouse lymphoma assay). Oxaliplatin was clastogenic  
358 both *in vitro* (chromosome aberration in human lymphocytes) and *in vivo* (mouse bone  
359 marrow micronucleus assay).

360

361 In a fertility study, male rats were given oxaliplatin at 0, 0.5, 1, or 2 mg/kg/day for five days  
362 every 21 days for a total of three cycles prior to mating with females that received two cycles  
363 of oxaliplatin on the same schedule. A dose of 2 mg/kg/day (less than one-seventh the  
364 recommended human dose on a body surface area basis) did not affect pregnancy rate, but  
365 caused developmental mortality (increased early resorptions, decreased live fetuses, decreased  
366 live births) and delayed growth (decreased fetal weight). Testicular damage, characterized by  
367 degeneration, hypoplasia, and atrophy, was observed in dogs administered oxaliplatin at 0.75  
368 mg/kg/day x 5 days every 28 days for three cycles. A no effect level was not identified. This  
369 daily dose is approximately one-sixth of the recommended human dose on a body surface area  
370 basis.

371

372 **Pregnancy Category D - See WARNINGS**

373 **Nursing Mothers** - It is not known whether ELOXATIN or its derivatives are excreted in  
374 human milk. Because many drugs are excreted in human milk and because of the potential  
375 for serious adverse reactions in nursing infants from ELOXATIN, a decision should be made  
376 whether to discontinue nursing or delay the use of the drug, taking into account the  
377 importance of the drug to the mother.

378

379 **Pediatric Use** - The safety and effectiveness of ELOXATIN in pediatric patients have not been  
380 established.

381

382 **Patients with Renal Impairment** The safety and effectiveness of the combination of  
383 ELOXATIN and 5-FU/LV in patients with renal impairment has not been evaluated. The  
384 combination of ELOXATIN and 5-FU/LV should be used with caution in patients with  
385 preexisting renal impairment since the primary route of platinum elimination is renal.  
386 Clearance of ultrafilterable platinum is decreased in patients with mild, moderate, and severe  
387 renal impairment. A pharmacodynamic relationship between platinum ultrafiltrate levels and  
388 clinical safety and effectiveness has not been established. (See CLINICAL  
389 PHARMACOLOGY and ADVERSE REACTIONS)

390



391 **Geriatric Use** - No significant effect of age on the clearance of ultrafilterable platinum has  
392 been observed. In the previously untreated for advanced colorectal cancer randomized  
393 clinical trial (see **CLINICAL STUDIES**) of ELOXATIN, 160 patients treated with ELOXATIN  
394 and 5-FU/LV were < 65 years and 99 patients were ≥ 65 years. The same efficacy  
395 improvements in response rate, time to tumor progression, and overall survival were observed  
396 in the ≥ 65 year old patients as in the overall study population. In the previously treated  
397 randomized clinical trial (see **CLINICAL STUDIES**) of ELOXATIN, 95 patients treated with  
398 ELOXATIN and 5-FU/LV were < 65 years and 55 patients were ≥ 65 years. The rates of overall  
399 adverse events, including grade 3 and 4 events, were similar across and within arms in the  
400 different age groups in both studies. The incidence of diarrhea, dehydration, hypokalemia,  
401 leukopenia, fatigue and syncope were higher in patients ≥ 65 years old. No adjustment to  
402 starting dose was required in patients ≥ 65 years old.

403

404 **Drug Interactions** - No specific cytochrome P-450-based drug interaction studies have been  
405 conducted. No pharmacokinetic interaction between 85 mg/m<sup>2</sup> ELOXATIN and 5-FU/LV has  
406 been observed in patients treated every 2 weeks. Increases of 5-FU plasma concentrations by  
407 approximately 20% have been observed with doses of 130 mg/m<sup>2</sup> ELOXATIN dosed every 3  
408 weeks. Since platinum containing species are eliminated primarily through the kidney,  
409 clearance of these products may be decreased by coadministration of potentially nephrotoxic  
410 compounds; although, this has not been specifically studied. (see **CLINICAL**  
411 **PHARMACOLOGY**)

412

413 **ADVERSE REACTIONS**

414

415 More than 4,000 patients with advanced colorectal cancer have been treated in clinical studies  
416 with ELOXATIN either as a single agent or in combination with other medications. The most  
417 common adverse reactions were peripheral sensory neuropathies, fatigue, neutropenia,  
418 nausea, emesis, and diarrhea (See PRECAUTIONS).

419

420 **Patients Previously Untreated for Advanced Colorectal Cancer**

421

422 Two-hundred and fifty nine patients were treated in the ELOXATIN and 5-FU/LV combination  
423 arm of the randomized trial in patients previously untreated for advanced colorectal cancer  
424 (See CLINICAL STUDIES). The adverse event profile in this study was similar to that seen  
425 in other studies and the adverse reactions in this trial are shown in the tables below.

426

427 Both 5-FU and ELOXATIN are associated with gastrointestinal and hematologic adverse events.  
428 When ELOXATIN is administered in combination with 5-FU, the incidence of these events is  
429 increased.

430

431 The incidence of death within 30 days of treatment in the previously untreated for advanced  
432 colorectal cancer study, regardless of causality, was 3% with the ELOXATIN and 5-FU/LV  
433 combination, 5% with irinotecan plus 5-FU/LV, and 3% with ELOXATIN plus irinotecan.  
434 Deaths within 60 days from initiation of therapy were 2.3% with the ELOXATIN and 5-FU/LV  
435 combination, 5.1% with irinotecan plus 5-FU/LV, and 3.1% with ELOXATIN plus irinotecan.

436

437 The following table provides adverse events reported in the previously untreated for advanced  
438 colorectal cancer study (see CLINICAL STUDIES) by body system and decreasing order of  
439 frequency in the ELOXATIN and 5-FU/LV combination arm for events with overall incidences  
440  $\geq 5\%$  and for grade 3/4 events with incidences  $\geq 1\%$ . This table does not include hematologic  
441 and blood chemistry abnormalities; these are shown separately below.

442

443 **Table 8 – Adverse Experience Reported in Patients Previously Untreated for Advanced**  
444 **Colorectal Cancer Clinical Trial**  
445 **( $\geq 5\%$  of all patients and with  $\geq 1\%$  NCI Grade 3/4 events)**

|                                                   | ELOXATIN + 5-FU/LV<br>N=259 |                  | irinotecan + 5-FU/LV<br>N=256 |                  | ELOXATIN + irinotecan<br>N=258 |                  |
|---------------------------------------------------|-----------------------------|------------------|-------------------------------|------------------|--------------------------------|------------------|
| Adverse Event<br>(WHO/Pref)                       | All<br>Grades (%)           | Grade<br>3/4 (%) | All<br>Grades (%)             | Grade<br>3/4 (%) | All<br>Grades (%)              | Grade<br>3/4 (%) |
| Any Event                                         | 99                          | 82               | 98                            | 70               | 99                             | 76               |
| <b>Allergy/Immunology</b>                         |                             |                  |                               |                  |                                |                  |
| Hypersensitivity                                  | 12                          | 2                | 5                             | 0                | 6                              | 1                |
| <b>Cardiovascular</b>                             |                             |                  |                               |                  |                                |                  |
| Thrombosis                                        | 6                           | 5                | 6                             | 6                | 3                              | 3                |
| Hypotension                                       | 5                           | 3                | 6                             | 3                | 4                              | 3                |
| <b>Constitutional Symptoms/Pain/Ocular/Visual</b> |                             |                  |                               |                  |                                |                  |
| Fatigue                                           | 70                          | 7                | 58                            | 11               | 66                             | 16               |
| Abdominal Pain                                    | 29                          | 8                | 31                            | 7                | 39                             | 10               |
| Myalgia                                           | 14                          | 2                | 6                             | 0                | 9                              | 2                |
| Pain                                              | 7                           | 1                | 5                             | 1                | 6                              | 1                |
| Vision abnormal                                   | 5                           | 0                | 2                             | 1                | 6                              | 1                |
| Neuralgia                                         | 5                           | 0                | 0                             | 0                | 2                              | 1                |
| <b>Dermatology/Skin</b>                           |                             |                  |                               |                  |                                |                  |
| Skin reaction – hand/foot                         | 7                           | 1                | 2                             | 1                | 1                              | 0                |
| Injection site reaction                           | 6                           | 0                | 1                             | 0                | 4                              | 1                |
| <b>Gastrointestinal</b>                           |                             |                  |                               |                  |                                |                  |
| Nausea                                            | 71                          | 6                | 67                            | 15               | 83                             | 19               |
| Diarrhea                                          | 56                          | 12               | 65                            | 29               | 76                             | 25               |
| Vomiting                                          | 41                          | 4                | 43                            | 13               | 64                             | 23               |
| Stomatitis                                        | 38                          | 0                | 25                            | 1                | 19                             | 1                |
| Anorexia                                          | 35                          | 2                | 25                            | 4                | 27                             | 5                |
| Constipation                                      | 32                          | 4                | 27                            | 2                | 21                             | 2                |
| Diarrhea-colostomy                                | 13                          | 2                | 16                            | 7                | 16                             | 3                |
| Gastrointestinal NOS                              | 5                           | 2                | 4                             | 2                | 3                              | 2                |
| <b>Hematology/Infection</b>                       |                             |                  |                               |                  |                                |                  |
| Infection no ANC                                  | 10                          | 4                | 5                             | 1                | 7                              | 2                |
| Infection –ANC                                    | 8                           | 8                | 12                            | 11               | 9                              | 8                |
| Lymphopenia                                       | 6                           | 2                | 4                             | 1                | 5                              | 2                |
| Febrile neutropenia                               | 4                           | 4                | 15                            | 14               | 12                             | 11               |
| <b>Hepatic/Metabolic/Laboratory/Renal</b>         |                             |                  |                               |                  |                                |                  |
| Hyperglycemia                                     | 14                          | 2                | 11                            | 3                | 12                             | 3                |
| Hypokalemia                                       | 11                          | 3                | 7                             | 4                | 6                              | 2                |
| Dehydration                                       | 9                           | 5                | 16                            | 11               | 14                             | 7                |
| Hypoalbuminemia                                   | 8                           | 0                | 5                             | 2                | 9                              | 1                |
| Hyponatremia                                      | 8                           | 2                | 7                             | 4                | 4                              | 1                |
| Urinary frequency                                 | 5                           | 1                | 2                             | 1                | 3                              | 1                |
| <b>Neurology</b>                                  |                             |                  |                               |                  |                                |                  |
| Overall Neuropathy                                | 82                          | 19               | 18                            | 2                | 69                             | 7                |
| Paresthesias                                      | 77                          | 18               | 16                            | 2                | 62                             | 6                |
| Pharyngo-laryngeal<br>dysesthesias                | 38                          | 2                | 1                             | 0                | 28                             | 1                |
| Neuro-sensory                                     | 12                          | 1                | 2                             | 0                | 9                              | 1                |
| Neuro NOS                                         | 1                           | 0                | 1                             | 0                | 1                              | 0                |
| <b>Pulmonary</b>                                  |                             |                  |                               |                  |                                |                  |
| Cough                                             | 35                          | 1                | 25                            | 2                | 17                             | 1                |
| Dyspnea                                           | 18                          | 7                | 14                            | 3                | 11                             | 2                |
| Hiccups                                           | 5                           | 1                | 2                             | 0                | 3                              | 2                |

446 The following table provides adverse events reported in the previously untreated for advanced  
447 colorectal cancer study (see CLINICAL STUDIES) by body system and decreasing order of

448 frequency in the ELOXATIN and 5-FU/LV combination arm for events with overall incidences  
 449  $\geq 5\%$  but with incidences  $< 1\%$  NCI Grade 3/4 events.

450

451 **Table 9 - Adverse Experience Reported in Patients Previously Untreated for Advanced**  
 452 **Colorectal Cancer Clinical Trial**

| ( $\geq 5\%$ of all patients but<br>with $< 1\%$ NCI Grade 3/4<br>events)<br>Adverse Event<br>(WHO/Pref) | ELOXATIN +<br>5-FU/LV<br>N=259<br>All Grades (%) | irinotecan + 5-FU/LV<br>N=256<br>All Grades (%) | ELOXATIN + irinotecan<br>N=258<br>All Grades (%) |
|----------------------------------------------------------------------------------------------------------|--------------------------------------------------|-------------------------------------------------|--------------------------------------------------|
|                                                                                                          | All<br>Grades (%)                                | All<br>Grades (%)                               | All<br>Grades (%)                                |
| <b>Allergy/Immunology</b>                                                                                |                                                  |                                                 |                                                  |
| Rash                                                                                                     | 11                                               | 4                                               | 7                                                |
| Rhinitis allergic                                                                                        | 10                                               | 6                                               | 6                                                |
| <b>Cardiovascular</b>                                                                                    |                                                  |                                                 |                                                  |
| Edema                                                                                                    | 15                                               | 13                                              | 10                                               |
| <b>Constitutional Symptoms/Pain/Ocular/Visual</b>                                                        |                                                  |                                                 |                                                  |
| Headache                                                                                                 | 13                                               | 6                                               | 9                                                |
| Weight loss                                                                                              | 11                                               | 9                                               | 11                                               |
| Epistaxis                                                                                                | 10                                               | 2                                               | 2                                                |
| Tearing                                                                                                  | 9                                                | 1                                               | 2                                                |
| Rigors                                                                                                   | 8                                                | 2                                               | 7                                                |
| Dysphasia                                                                                                | 5                                                | 3                                               | 3                                                |
| Sweating                                                                                                 | 5                                                | 6                                               | 12                                               |
| Arthralgia                                                                                               | 5                                                | 5                                               | 8                                                |
| <b>Dermatology/Skin</b>                                                                                  |                                                  |                                                 |                                                  |
| Alopecia                                                                                                 | 38                                               | 44                                              | 67                                               |
| Flushing                                                                                                 | 7                                                | 2                                               | 5                                                |
| Pruritis                                                                                                 | 6                                                | 4                                               | 2                                                |
| Dry Skin                                                                                                 | 6                                                | 2                                               | 5                                                |
| <b>Gastrointestinal</b>                                                                                  |                                                  |                                                 |                                                  |
| Taste perversion                                                                                         | 14                                               | 6                                               | 8                                                |
| Dyspepsia                                                                                                | 12                                               | 7                                               | 5                                                |
| Flatulence                                                                                               | 9                                                | 6                                               | 5                                                |
| Mouth Dryness                                                                                            | 5                                                | 2                                               | 3                                                |
| <b>Hematology/Infection</b>                                                                              |                                                  |                                                 |                                                  |
| Fever no ANC                                                                                             | 16                                               | 9                                               | 9                                                |
| <b>Hepatic/Metabolic/Laboratory/Renal</b>                                                                |                                                  |                                                 |                                                  |
| Hypocalcemia                                                                                             | 7                                                | 5                                               | 4                                                |
| Elevated Creatinine                                                                                      | 4                                                | 4                                               | 5                                                |
| <b>Neurology</b>                                                                                         |                                                  |                                                 |                                                  |
| Insomnia                                                                                                 | 13                                               | 9                                               | 11                                               |
| Depression                                                                                               | 9                                                | 5                                               | 7                                                |
| Dizziness                                                                                                | 8                                                | 6                                               | 10                                               |
| Anxiety                                                                                                  | 5                                                | 2                                               | 6                                                |

453

454 Adverse events were similar in men and women and in patients <65 and ≥65 years, but older  
455 patients may have been more susceptible to diarrhea, dehydration, hypokalemia, leukopenia,  
456 fatigue and syncope. The following additional adverse events, at least possibly related to  
457 treatment and potentially important, were reported in ≥2% and <5% of the patients in the  
458 ELOXATIN and 5-FU/LV combination arm (listed in decreasing order of frequency): metabolic,  
459 pneumonitis, catheter infection, vertigo, prothrombin time, pulmonary, rectal bleeding,  
460 dysuria, nail changes, chest pain, rectal pain, syncope, hypertension, hypoxia, unknown  
461 infection, bone pain, pigmentation changes, and urticaria.

462

### 463 **Previously Treated Patients with Advanced Colorectal Cancer**

464

465 Four-hundred and fifty patients (about 150 receiving the combination of ELOXATIN and 5-  
466 FU/LV) were studied in a randomized trial in patients with refractory and relapsed colorectal  
467 cancer (See CLINICAL STUDIES). The adverse event profile in this study was similar to  
468 that seen in other studies and the adverse reactions in this trial are shown in the tables below.

469

470 Thirteen per cent of patients in the ELOXATIN and 5-FU/LV-combination arm and 18% in the  
471 5-FU/LV arm of the previously treated study had to discontinue treatment because of adverse  
472 effects related to gastrointestinal, or hematologic adverse events, or neuropathies. Both 5-FU  
473 and ELOXATIN are associated with gastrointestinal and hematologic adverse events. When  
474 ELOXATIN is administered in combination with 5-FU, the incidence of these events is  
475 increased.

476

477 The incidence of death within 30 days of treatment in the previously treated study, regardless  
478 of causality, was 5% with the ELOXATIN and 5-FU/LV combination, 8% with ELOXATIN alone,  
479 and 7% with 5-FU/LV. Of the 7 deaths that occurred on the ELOXATIN and 5-FU/LV  
480 combination arm within 30 days of stopping treatment, 3 may have been treatment related,  
481 associated with gastrointestinal bleeding or dehydration

482

483 The following table provides adverse events reported in the previously treated study (see  
484 CLINICAL STUDIES) by body system and in decreasing order of frequency in the ELOXATIN  
485 and 5-FU/LV combination arm for events with overall incidences ≥5% and for grade 3/4  
486 events with incidences ≥ 1%. This table does not include hematologic and blood chemistry  
487 abnormalities; these are shown separately below.

**Table 10 – Adverse Experience Reported In Previously Treated  
Colorectal Cancer Clinical Trial  
(≥5% of all patients and with ≥1% NCI Grade 3/4 events)**

|                                           | 5-FU/LV<br>(N = 142) |                  | ELOXATIN<br>(N = 153) |                  | ELOXATIN + 5-FU/LV<br>(N = 150) |                  |
|-------------------------------------------|----------------------|------------------|-----------------------|------------------|---------------------------------|------------------|
| Adverse Event<br>(WHO/Pref)               | All<br>Grades (%)    | Grade<br>3/4 (%) | All<br>Grades (%)     | Grade<br>3/4 (%) | All<br>Grades (%)               | Grade<br>3/4 (%) |
| Any Event                                 | 98                   | 41               | 100                   | 46               | 99                              | 73               |
| <b>Cardiovascular</b>                     |                      |                  |                       |                  |                                 |                  |
| Dyspnea                                   | 11                   | 2                | 13                    | 7                | 20                              | 4                |
| Coughing                                  | 9                    | 0                | 11                    | 0                | 19                              | 1                |
| Edema                                     | 13                   | 1                | 10                    | 1                | 15                              | 1                |
| Thromboembolism                           | 4                    | 2                | 2                     | 1                | 9                               | 8                |
| Chest Pain                                | 4                    | 1                | 5                     | 1                | 8                               | 1                |
| <b>Constitutional Symptoms/Pain</b>       |                      |                  |                       |                  |                                 |                  |
| Fatigue                                   | 52                   | 6                | 61                    | 9                | 68                              | 7                |
| Back Pain                                 | 16                   | 4                | 11                    | 0                | 19                              | 3                |
| Pain                                      | 9                    | 3                | 14                    | 3                | 15                              | 2                |
| <b>Dermatology/Skin</b>                   |                      |                  |                       |                  |                                 |                  |
| Injection Site Reaction                   | 5                    | 1                | 9                     | 0                | 10                              | 3                |
| <b>Gastrointestinal</b>                   |                      |                  |                       |                  |                                 |                  |
| Diarrhea                                  | 44                   | 3                | 46                    | 4                | 67                              | 11               |
| Nausea                                    | 59                   | 4                | 64                    | 4                | 65                              | 11               |
| Vomiting                                  | 27                   | 4                | 37                    | 4                | 40                              | 9                |
| Stomatitis                                | 32                   | 3                | 14                    | 0                | 37                              | 3                |
| Abdominal Pain                            | 31                   | 5                | 31                    | 7                | 33                              | 4                |
| Anorexia                                  | 20                   | 1                | 20                    | 2                | 29                              | 3                |
| Gastroesophageal Reflux                   | 3                    | 0                | 1                     | 0                | 5                               | 2                |
| <b>Hematology/Infection</b>               |                      |                  |                       |                  |                                 |                  |
| Fever                                     | 23                   | 1                | 25                    | 1                | 29                              | 1                |
| Febrile Neutropenia                       | 1                    | 1                | 0                     | 0                | 6                               | 6                |
| <b>Hepatic/Metabolic/Laboratory/Renal</b> |                      |                  |                       |                  |                                 |                  |
| Hypokalemia                               | 3                    | 1                | 3                     | 2                | 9                               | 4                |
| Dehydration                               | 6                    | 4                | 5                     | 3                | 8                               | 3                |
| <b>Neurology</b>                          |                      |                  |                       |                  |                                 |                  |
| Neuropathy                                | 17                   | 0                | 76                    | 7                | 74                              | 7                |
| Acute                                     | 10                   | 0                | 65                    | 5                | 56                              | 2                |
| Persistent                                | 9                    | 0                | 43                    | 3                | 48                              | 6                |

The following table provides adverse events reported in the previously treated study (see CLINICAL STUDIES) by body system and in decreasing order of frequency in the ELOXATIN and 5-FU/LV combination arm for events with overall incidences ≥5% but with incidences < 1% NCI Grade 3/4 events.

497  
498  
499  
500

**Table 11 - Adverse Experience Reported In Previously Treated Colorectal Cancer Clinical Trial**  
(≥5% of all patients but with < 1% NCI Grade 3/4 events)

| Adverse Event<br>(WHO/Pref)                       | 5-FU/LV<br>(N = 142)<br>All Grades (%) | ELOXATIN<br>(N = 153)<br>All Grades (%) | ELOXATIN + 5-FU/LV<br>(N = 150)<br>All Grades (%) |
|---------------------------------------------------|----------------------------------------|-----------------------------------------|---------------------------------------------------|
|                                                   | All<br>Grades (%)                      | All<br>Grades (%)                       | All<br>Grades (%)                                 |
| <b>Allergy/Immunology</b>                         |                                        |                                         |                                                   |
| Rhinitis                                          | 4                                      | 6                                       | 15                                                |
| Allergic Reaction                                 | 1                                      | 3                                       | 10                                                |
| Rash                                              | 5                                      | 5                                       | 9                                                 |
| <b>Cardiovascular</b>                             |                                        |                                         |                                                   |
| Peripheral Edema                                  | 11                                     | 5                                       | 10                                                |
| <b>Constitutional Symptoms/Pain/Ocular/Visual</b> |                                        |                                         |                                                   |
| Headache                                          | 8                                      | 13                                      | 17                                                |
| Arthralgia                                        | 10                                     | 7                                       | 10                                                |
| Epistaxis                                         | 1                                      | 2                                       | 9                                                 |
| Abnormal Lacrimation                              | 6                                      | 1                                       | 7                                                 |
| Rigors                                            | 6                                      | 9                                       | 7                                                 |
| <b>Dermatology/Skin</b>                           |                                        |                                         |                                                   |
| Hand-Foot Syndrome                                | 13                                     | 1                                       | 11                                                |
| Flushing                                          | 2                                      | 3                                       | 10                                                |
| Alopecia                                          | 3                                      | 3                                       | 7                                                 |
| <b>Gastrointestinal</b>                           |                                        |                                         |                                                   |
| Constipation                                      | 23                                     | 31                                      | 32                                                |
| Dyspepsia                                         | 10                                     | 7                                       | 14                                                |
| Taste Perversion                                  | 1                                      | 5                                       | 13                                                |
| Mucositis                                         | 10                                     | 2                                       | 7                                                 |
| Flatulence                                        | 6                                      | 3                                       | 5                                                 |
| <b>Hepatic/Metabolic/Laboratory/Renal</b>         |                                        |                                         |                                                   |
| Hematuria                                         | 4                                      | 0                                       | 6                                                 |
| Dysuria                                           | 1                                      | 1                                       | 6                                                 |
| <b>Neurology</b>                                  |                                        |                                         |                                                   |
| Dizziness                                         | 8                                      | 7                                       | 13                                                |
| Insomnia                                          | 4                                      | 11                                      | 9                                                 |
| <b>Pulmonary</b>                                  |                                        |                                         |                                                   |
| Upper Resp Tract Infection                        | 4                                      | 7                                       | 10                                                |
| Pharyngitis                                       | 10                                     | 2                                       | 9                                                 |
| Hiccup                                            | 0                                      | 2                                       | 5                                                 |

501

Adverse events were similar in men and women and in patients <65 and ≥65 years, but older patients may have been more susceptible to dehydration, diarrhea, hypokalemia and fatigue. The following additional adverse events, at least possibly related to treatment and potentially important, were reported in ≥2% and <5% of the patients in the ELOXATIN and 5-FU/LV combination arm (listed in decreasing order of frequency): anxiety, myalgia, erythematous rash, increased sweating, conjunctivitis, weight decrease, dry mouth, rectal hemorrhage, depression, ataxia, ascites, hemorrhoids, muscle weakness, nervousness, tachycardia, abnormal micturition frequency, dry skin, pruritis, hemoptysis, purpura, vaginal hemorrhage, melena, somnolence, pneumonia, proctitis, involuntary muscle contractions, intestinal obstruction, gingivitis, tenesmus, hot flashes, enlarged abdomen, urinary incontinence.

### Hematologic

The following tables list the hematologic changes occurring in ≥5% of patients, based on laboratory values and NCI grade, with the exception of anemia in the patients previously untreated for advanced colorectal cancer, which is based on AE reporting and NCI grade alone.

**Table 12 – Adverse Hematologic Experiences in Patients Previously Untreated for Advanced Colorectal Cancer (≥5% of patients)**

| Hematology Parameter | ELOXATIN + 5-FU/LV<br>N=259 |               | irinotecan+ 5-FU/LV<br>N=256 |               | ELOXATIN + irinotecan<br>N=258 |               |
|----------------------|-----------------------------|---------------|------------------------------|---------------|--------------------------------|---------------|
|                      | All Grades (%)              | Grade 3/4 (%) | All Grades (%)               | Grade 3/4 (%) | All Grades (%)                 | Grade 3/4 (%) |
| Anemia               | 27                          | 3             | 28                           | 4             | 25                             | 3             |
| Leukopenia           | 85                          | 20            | 84                           | 23            | 76                             | 24            |
| Neutropenia          | 81                          | 53            | 77                           | 44            | 71                             | 36            |
| Thrombocytopenia     | 71                          | 5             | 26                           | 2             | 44                             | 4             |

**Table 13 – Adverse Hematologic Experiences Previously Treated Patients (≥5% of patients)**

| Hematology Parameter | 5-FU/LV<br>(N=142) |               | ELOXATIN<br>(N=153) |               | ELOXATIN + 5-FU/LV<br>(N=150) |               |
|----------------------|--------------------|---------------|---------------------|---------------|-------------------------------|---------------|
|                      | All Grades (%)     | Grade 3/4 (%) | All Grades (%)      | Grade 3/4 (%) | All Grades (%)                | Grade 3/4 (%) |
| Anemia               | 68                 | 2             | 64                  | 1             | 81                            | 2             |
| Leukopenia           | 34                 | 1             | 13                  | 0             | 76                            | 19            |
| Neutropenia          | 25                 | 5             | 7                   | 0             | 73                            | 44            |
| Thrombocytopenia     | 20                 | 0             | 30                  | 3             | 64                            | 4             |



## 526 Thrombocytopenia

527 Thrombocytopenia was frequently reported with the combination of ELOXATIN and 5-FU/LV.  
528 The incidence of Grade 3/4 thrombocytopenia in the patients previously untreated for  
529 advanced colorectal cancer and the previously treated patients was 3-5%. Grade 3/4  
530 hemorrhagic events in both patient populations were reported at low frequency and the  
531 incidence of these events were greater for the combination of ELOXATIN and 5-FU/LV over  
532 the irinotecan plus 5-FU/LV or 5-FU/LV control groups. In the previously untreated patients,  
533 the incidence of epistaxis was 10% in the ELOXATIN and 5-FU/LV arm, and 2% and 1%  
534 respectively in the irinotecan plus 5-FU/LV or irinotecan plus ELOXATIN arms. The  
535 requirement for platelet transfusion was not increased in the ELOXATIN and 5-FU/LV arm.  
536 The incidence of all hemorrhagic events in the previously treated patients was also higher on  
537 the ELOXATIN combination arm compared to the 5-FU/LV arm. These events included  
538 gastrointestinal bleeding, hematuria and epistaxis.

## 539 540 Neutropenia

541 Neutropenia was frequently observed with the combination of ELOXATIN and 5-FU/LV, with  
542 Grade 3 and 4 events reported in 35% and 18% of the patients previously untreated for  
543 advanced colorectal cancer, respectively. Grade 3 and 4 events were reported in 27% and  
544 17% of previously treated patients, respectively. The incidence of febrile neutropenia in the  
545 patients previously untreated for advanced colorectal cancer was 15% (3% of cycles) in the  
546 irinotecan plus 5-FU/LV arm and 4% (less than 1% of cycles) in the ELOXATIN and 5-FU/LV  
547 combination arm. Additionally, in this same population, infection with grade 3 or 4  
548 neutropenia was 12% in the irinotecan plus 5-FU/LV, and 8% in the ELOXATIN and 5-FU/LV  
549 combination. The incidence of febrile neutropenia in the previously treated patients was 1%  
550 in the 5-FU/LV arm and 6% (less than 1% of cycles) in the ELOXATIN and 5-FU/LV  
551 combination arm.

## 552 553 Gastrointestinal

554 In patients previously untreated for advanced colorectal cancer receiving the combination of  
555 ELOXATIN and 5-FU/LV, the incidence of Grade 3 and 4 vomiting and diarrhea was less  
556 compared to irinotecan plus 5-FU/LV controls (See table). In previously treated patients  
557 receiving the combination of ELOXATIN and 5-FU/LV, the incidence of Grade 3 and 4 nausea,  
558 vomiting, diarrhea, and mucositis/stomatitis increased compared to 5-FU/LV controls (See  
559 table).

560  
561 The incidence of gastrointestinal adverse events in the previously untreated and previously  
562 treated patients appears to be similar across cycles. Premedication with antiemetics,  
563 including 5-HT<sub>3</sub> blockers, is recommended. Diarrhea and mucositis may be exacerbated by  
564 the addition of ELOXATIN to 5-FU/LV, and should be managed with appropriate supportive  
565 care. Since cold temperature can exacerbate acute neurological symptoms, ice (mucositis  
566 prophylaxis) should be avoided during the infusion of ELOXATIN.

567

568 **Dermatologic**

569 ELOXATIN did not increase the incidence of alopecia compared to 5-FU/LV alone. No  
570 complete alopecia was reported. The incidence of hand-foot syndrome in patients previously  
571 untreated for advanced colorectal cancer was 2% in the irinotecan plus 5-FU/LV arm and 7%  
572 in the ELOXATIN and 5-FU/LV combination arm. The incidence of hand-foot syndrome in  
573 previously treated patients was 13% in the 5-FU/LV arm and 11% in the ELOXATIN and 5-  
574 FU/LV combination arm.

575

576 **Care of Intravenous Site:**

577 Extravasation may result in local pain and inflammation that may be severe and lead to  
578 complications, including necrosis. Injection site reaction, including redness, swelling, and  
579 pain have been reported.

580

581 **Neurologic**

582 Overall, neuropathy was reported in patients previously untreated for advanced colorectal  
583 cancer in 82% (all grades) and 19% (grade 3/4), and in the previously treated patients in 74%  
584 (all grades) and 7% (grade 3/4) events. ELOXATIN is consistently associated with two types of  
585 peripheral neuropathy (see PRECAUTIONS, Neuropathy). In the previously treated  
586 patients, the incidence of overall and Grade 3/4 persistent peripheral neuropathy was 48% and  
587 6%, respectively. The majority of the patients (80%) that developed grade 3 persistent  
588 neuropathy progressed from prior Grade 1 or 2 events. The median number of cycles  
589 administered on the ELOXATIN with 5-FU/LV combination arm in the previously treated  
590 patients was 6.

591

592 **Pulmonary**

593

594 ELOXATIN has been associated with pulmonary fibrosis (see PRECAUTIONS, Pulmonary  
595 Toxicity).

596

597 **Allergic reactions**

598 Hypersensitivity to ELOXATIN has been observed (<2% Grade 3/4) in clinical studies. These  
599 allergic reactions which can be fatal, can occur at any cycle, and were similar in nature and  
600 severity to those reported with other platinum-containing compounds such as, rash, urticaria,  
601 erythema, pruritis, and, rarely, bronchospasm and hypotension. The symptoms associated  
602 with hypersensitivity reactions reported in the previously untreated patients were urticaria,  
603 pruritis, flushing of the face, diarrhea associated with oxaliplatin infusion, shortness of breath,  
604 bronchospasm, diaphoresis, chest pains, hypotension, disorientation and syncope. These  
605 reactions are usually managed with standard epinephrine, corticosteroid, antihistamine  
606 therapy, and may require discontinuation of therapy. (see WARNINGS for  
607 anaphylactic/anaphylactoid reactions.)

608

609 **Anticoagulation and Hemorrhage**

610

There have been reports while on study and from post-marketing surveillance of prolonged prothrombin time and INR occasionally associated with hemorrhage in patients who received ELOXATIN plus 5-FU/LV while on anticoagulants. Patients receiving ELOXATIN plus 5-FU/LV and requiring oral anticoagulants may require closer monitoring.

## Renal

About 5-10% of patients in all groups had some degree of elevation of serum creatinine. The incidence of Grade 3/4 elevations in serum creatinine in the ELOXATIN and 5-FU/LV combination arm was 1% in the previously treated patients

## Hepatic

The following tables list the clinical chemistry changes associated with hepatic toxicity occurring in  $\geq 5\%$  of patients, based on adverse events reported and NCI CTC grade for patients previously untreated for advanced colorectal cancer, laboratory values and NCI CTC grade for previously treated patients.

**Table 14 – Adverse Hepatic – Clinical Chemistry Experience in Patients Previously Untreated for Advanced Colorectal Cancer ( $\geq 5\%$  of patients)**

| Clinical Chemistry   | ELOXATIN + 5-FU/LV<br>N=259 |               | irinotecan + 5-FU/LV<br>N=256 |               | ELOXATIN + irinotecan<br>N=258 |               |
|----------------------|-----------------------------|---------------|-------------------------------|---------------|--------------------------------|---------------|
|                      | All Grades (%)              | Grade 3/4 (%) | All Grades (%)                | Grade 3/4 (%) | All Grades (%)                 | Grade 3/4 (%) |
| ALT (SGPT-ALAT)      | 6                           | 1             | 2                             | 0             | 5                              | 2             |
| AST (SGOT-ASAT)      | 17                          | 1             | 2                             | 1             | 11                             | 1             |
| Alkaline Phosphatase | 16                          | 0             | 8                             | 0             | 14                             | 2             |
| Total Bilirubin      | 6                           | 1             | 3                             | 1             | 3                              | 2             |

**Table 15 – Adverse Hepatic – Clinical Chemistry Experience in Previously Treated Patients ( $\geq 5\%$  of patients)**

| Clinical Chemistry | 5-FU/LV<br>(N=142) |               | ELOXATIN<br>(N=153) |               | ELOXATIN + 5-FU/LV<br>(N=150) |               |
|--------------------|--------------------|---------------|---------------------|---------------|-------------------------------|---------------|
|                    | All Grades (%)     | Grade 3/4 (%) | All Grades (%)      | Grade 3/4 (%) | All Grades (%)                | Grade 3/4 (%) |
| ALT (SGPT-ALAT)    | 28                 | 3             | 36                  | 1             | 31                            | 0             |
| AST (SGOT-ASAT)    | 39                 | 2             | 54                  | 4             | 47                            | 0             |
| Total Bilirubin    | 22                 | 6             | 13                  | 5             | 13                            | 1             |

637 **Thromboembolism**

638

639 The incidence of thromboembolic events was 6 and 9% of the patients previously untreated  
640 for advanced colorectal cancer and previously treated patients in the ELOXATIN and 5-FU/LV  
641 combination arm, respectively.

642

643 **Postmarketing Experience**

644

645 The following events have been reported from worldwide postmarketing experience.

646

647 Body as a whole:

648 -angioedema, anaphylactic shock

649

650 Central and peripheral nervous system disorders:

651 -loss of deep tendon reflexes, dysarthria, Lhermittes' sign, cranial nerve palsies,  
652 fasciculations

653

654 Gastrointestinal system disorders:

655 -severe diarrhea/vomiting resulting in hypokalemia, metabolic acidosis; ileus; intestinal  
656 obstruction, pancreatitis

657

658 Hearing and vestibular system disorders:

659 -deafness

660

661 Platelet, bleeding, and clotting disorders:

662 -immuno-allergic thrombocytopenia

663 -prolongation of prothrombin time and of INR in patients receiving anticoagulants

664

665 Red Blood Cell disorders

666 -hemolytic uremic syndrome

667

668 Respiratory system disorders:

669 -pulmonary fibrosis, and other interstitial lung diseases

670

671 Vision disorders:

672 -decrease of visual acuity, visual field disturbance, optic neuritis

673

## OVERDOSAGE

There have been five ELOXATIN overdoses reported. One patient received two 130 mg/m<sup>2</sup> doses of ELOXATIN (cumulative dose of 260 mg/m<sup>2</sup>) within a 24 hour period. The patient experienced Grade 4 thrombocytopenia (<25,000/mm<sup>3</sup>) without any bleeding, which resolved. Two other patients were mistakenly administered ELOXATIN instead of carboplatin. One patient received a total ELOXATIN dose of 500 mg and the other received 650 mg. The first patient experienced dyspnea, wheezing, paresthesia, profuse vomiting and chest pain on the day of administration. She developed respiratory failure and severe bradycardia, and subsequently did not respond to resuscitation efforts. The other patient also experienced dyspnea, wheezing, paresthesia, and vomiting. Her symptoms resolved with supportive care. Another patient who was mistakenly administered a 700 mg dose experienced rapid onset of dysesthesia. Inpatient supportive care was given, including hydration, electrolyte support, and platelet transfusion. Recovery occurred 15 days after the overdose. The last patient received an overdose of oxaliplatin at 360 mg instead of 120 mg over a 1-hour infusion by mistake. At the end of the infusion, the patient experienced 2 episodes of vomiting, laryngospasm, and paresthesia. The patient fully recovered from the laryngospasm within half an hour. At the time of reporting, 1 hour after onset of the event, the patient was recovering from paresthesia. There is no known antidote for ELOXATIN overdose. In addition to thrombocytopenia, the anticipated complications of an ELOXATIN overdose include myelosuppression, nausea and vomiting, diarrhea, and neurotoxicity. Patients suspected of receiving an overdose should be monitored, and supportive treatment should be administered.


## DOSAGE AND ADMINISTRATION

The recommended dose schedule given every two weeks is as follows:

**Day 1:** ELOXATIN 85 mg/m<sup>2</sup> IV infusion in 250-500 mL D5W and leucovorin 200 mg/m<sup>2</sup> IV infusion in D5W both given over 120 minutes at the same time in separate bags using a Y-line, followed by 5-FU 400 mg/m<sup>2</sup> IV bolus given over 2-4 minutes, followed by 5-FU 600 mg/m<sup>2</sup> IV infusion in 500 mL D5W (recommended) as a 22-hour continuous infusion.

**Day 2:** Leucovorin 200 mg/m<sup>2</sup> IV infusion over 120 minutes, followed by 5-FU 400 mg/m<sup>2</sup> IV bolus given over 2-4 minutes, followed by 5-FU 600 mg/m<sup>2</sup> IV infusion in 500 mL D5W (recommended) as a 22-hour continuous infusion.

Figure 2



Repeat cycle every 2 weeks.

The administration of ELOXATIN does not require prehydration.

Premedication with antiemetics, including 5-HT<sub>3</sub> blockers with or without dexamethasone, is recommended.

For information on 5-fluorouracil and leucovorin, see the respective package inserts.

### Dose Modification Recommendations

Prior to subsequent therapy cycles, patients should be evaluated for clinical toxicities and laboratory tests (see Laboratory Tests). Neuropathy was graded using a study-specific neurotoxicity scale (see PRECAUTIONS, Neuropathy). Other toxicities were graded by the NCI CTC, Version 2.0.

Prolongation of infusion time for ELOXATIN from 2 hours to 6 hours decreases the C<sub>max</sub> by an estimated 32% and may mitigate acute toxicities. The infusion time for 5-FU and leucovorin do not need to be changed.

For patients who experience persistent Grade 2 neurosensory events that do not resolve, a dose reduction of ELOXATIN to 65 mg/m<sup>2</sup> should be considered. For patients with persistent

735 Grade 3 neurosensory events, discontinuing therapy should be considered. The 5-FU/LV  
736 regimen need not be altered.

737

738 A dose reduction of ELOXATIN to 65 mg/m<sup>2</sup> and 5-FU by 20% (300 mg/m<sup>2</sup> bolus and 500  
739 mg/m<sup>2</sup> 22 hour infusion) is recommended for patients after recovery from grade 3/4  
740 gastrointestinal (despite prophylactic treatment) or grade 4 neutropenia or grade 3/4  
741 thrombocytopenia. The next dose should be delayed until: neutrophils  $\geq 1.5 \times 10^9/L$ , and  
742 platelets  $\geq 75 \times 10^9/L$ .

743

#### 744 Preparation of Infusion Solution

745 **RECONSTITUTION OR FINAL DILUTION MUST NEVER BE PERFORMED WITH**  
746 **A SODIUM CHLORIDE SOLUTION OR OTHER CHLORIDE-CONTAINING**  
747 **SOLUTIONS.**

748

749 The lyophilized powder is reconstituted by adding 10 mL (for the 50 mg vial) or 20 mL (for  
750 the 100 mg vial) of Water for Injection, USP or 5% Dextrose Injection, USP. **Do not**  
751 **administer the reconstituted solution without further dilution.** The reconstituted solution  
752 must be further diluted in an infusion solution of 250-500 mL of 5% Dextrose Injection, USP.

753

754 After reconstitution in the original vial, the solution may be stored up to 24 hours under  
755 refrigeration [2-8°C (36-46°F)]. After final dilution with 250-500 mL of  
756 5% Dextrose Injection, USP, the shelf life is **6 hours at room temperature [20-25°C (68-**  
757 **77°F)] or up to 24 hours under refrigeration [2-8°C (36-46°F)].** ELOXATIN is not light  
758 sensitive.

759

760 ELOXATIN is incompatible in solution with alkaline medications or media (such as basic  
761 solutions of 5-FU) and must not be mixed with these or administered simultaneously through  
762 the same infusion line. **The infusion line should be flushed with D5W prior to**  
763 **administration of any concomitant medication.**

764

765 Parenteral drug products should be inspected visually for particulate matter and discoloration  
766 prior to administration and discarded if present.

767

768 Needles or intravenous administration sets containing aluminum parts that may come in  
769 contact with ELOXATIN should not be used for the preparation or mixing of the drug.  
770 Aluminum has been reported to cause degradation of platinum compounds.

771

772 **HOW SUPPLIED**

773

774 ELOXATIN is supplied in clear, glass, single-use vials with gray elastomeric stoppers and  
775 aluminum flip-off seals containing 50 mg or 100 mg of oxaliplatin as a sterile, preservative-  
776 free lyophilized powder for reconstitution. Lactose monohydrate is also present as an inactive  
777 ingredient.

778

779 NDC 0024-0596-02: 50 mg single-use vial with green flip-off seal individually packaged in a  
780 carton.

781

782 NDC 0024-0597-04: 100 mg single-use vial with dark blue flip-off seal individually packaged  
783 in a carton.

784

785 **Storage**

786 Store under normal lighting conditions at 25°C (77°F); excursions permitted to 15-30°C  
787 (59-86°F) [see USP controlled room temperature].

788

789 **Handling and Disposal**

790 As with other potentially toxic anticancer agents, care should be exercised in the handling and  
791 preparation of infusion solutions prepared from ELOXATIN. The use of gloves is  
792 recommended. If a solution of ELOXATIN contacts the skin, wash the skin immediately and  
793 thoroughly with soap and water. If ELOXATIN contacts the mucous membranes, flush  
794 thoroughly with water.

795

796 Procedures for the handling and disposal of anticancer drugs should be considered. Several  
797 guidelines on the subject have been published [1-8]. There is no general agreement that all of  
798 the procedures recommended in the guidelines are necessary or appropriate.

799



800 **REFERENCES**

- 801
- 802 1. ONS Clinical Practice Committee. Cancer Chemotherapy Guidelines and  
803 Recommendations for Practice. Pittsburgh, Pa: Oncology Nursing Society; 1999:32-41.
- 804 2. Recommendations for the safe handling of parenteral antineoplastic drugs. NIH  
805 Publication No. 83-2621. For sale by the Superintendent of Documents, U.S.  
806 Government Printing Office, Washington, D.C. 20402.
- 807 3. AMA Council Report. Guidelines for handling parenteral antineoplastics. *JAMA*  
808 1985;253(11):1590-1592.
- 809 4. National Study Commission on Cytotoxic Exposure. Recommendations for handling  
810 cytotoxic agents. Available from Louis P. Jeffrey, Sc.D., Chairman, National  
811 Study Commission on Cytotoxic Exposure, Massachusetts College of Pharmacy and  
812 Allied Health Sciences, 179 Longwood Avenue, Boston, MA 02115.
- 813 5. Clinical Oncological Society of Australia. Guidelines and recommendations for safe  
814 handling of antineoplastic agents. *Med J Australia* 1983;1:426-428.
- 815 6. Jones RB, et al. Safe handling of chemotherapeutic agents: a report from the Mount Sinai  
816 Medical Center. *Ca - A Cancer Journal for Clinicians*. Sept./Oct. 1983:258-263.
- 817 7. American Society of Hospital Pharmacists. ASHP Technical Assistance Bulletin on  
818 handling cytotoxic and hazardous drugs. *Am J Hosp Pharm* 1990;47:1033-1049.
- 819 8. Controlling Occupational Exposure to Hazardous Drugs. (OSHA Work-Practice  
820 Guidelines). *Am J Hosp Pharm* 1996;53:1669-1685.

821  
822  
823  
824 Distributed by Sanofi-Synthelabo Inc.  
825 New York, NY 10016

826  
827 Manufactured for Sanofi-Synthelabo Inc. by Ben Venue Laboratories  
828 Bedford, Ohio 44146-0568  
829 Made in USA

830  
831 Printed in USA  
832 Date of Revision  
833